A phase III randomized trial for frail newly diagnosed multiple myeloma patients comparing bortezomib-lenalidomide-dexamethasone (VRd-lite followed by len maintenance) with daratumumab-lenalidomide-dexamethasone (DRd followed by len+/- dara maintenance): SWOG S2209 Meeting Abstract
| Authors: | Ailawadhi, S.; Hoering, A.; Ye, J. C.; Lipe, B.; Chauncey, T. R.; Gowin, K.; Calverley, D.; Holstein, S. A.; Campagnaro, E. L.; Rosenthal, A.; Aiello, J.; Usmani, S. Z.; Rajkumar, V.; Orlowski, R. Z. |
| Abstract Title: | A phase III randomized trial for frail newly diagnosed multiple myeloma patients comparing bortezomib-lenalidomide-dexamethasone (VRd-lite followed by len maintenance) with daratumumab-lenalidomide-dexamethasone (DRd followed by len+/- dara maintenance): SWOG S2209 |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 33813 |
| Language: | English |
| ACCESSION: | WOS:001412651600050 |
| DOI: | 10.1182/blood-2024-209626 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
